While having one of the 118 health conditions doesn't automatically mean being unable to drive the DVLA still needs to be ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced third-quarter 2025 financial results and a clinical ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min National celebrity Bill Nye ...

The backpack, known as the Gyropack, uses gyroscopic technology similar to that used in space stations or large satellites to maintain orientation in space. An innovative backpack, incorporating ...

Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

OKLAHOMA CITY – A University of Oklahoma researcher is the first to discover that the sequence of the genetic defect in the neuromuscular disease Friedreich’s ataxia isn’t always as uniform as ...

Cerebellar ataxia results from dysfunction of the cerebellum, which is part of the brain that helps regulate and control movement and balance. People may experience changes in gait, speech, and eye ...

Apraxia is a neurological disorder that affects the mental processes involved in planning, task performance, and more. Ataxia is a neurological sign affecting muscle coordination and movement.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.